Breaking milestones reached in project aiming to improve prevention and care of Metabolic dysfunction-Associated SteatoHepatitis (MASH).
Utrecht, The Netherlands, 17-12-2024: GRIPonMASH, a consortium dedicated to bring about a transformational change in the detection and diagnosis of MASH patients at different levels of health care management, completed its first year of research. GRIPonMASH focuses on designing and optimizing a sustainable and scalable GRIPonMASH diagnostic platform.
First patient successfully screened
A significant milestone achieved during the first year was the inclusion of the first patient in the study in Rotterdam. Other sites followed suit in including patients for the screening in the study. This will allow the consortium to set-up a biobank and data science platform to test both existing and novel biomarkers, and to leverage artificial intelligence-based technology to improve the detection of MASH. In the coming year all 12 hospitals/research institutes in the consortium will start screening patients to reach the target of 10.000 patients screened as stated in the agreement.
Pilot diagnostic platform
The first year also saw the development of the GRIPonMASH diagnostic platform by ways of a pilot study conducted at Amsterdam UMC. When tested sufficiently, the platform will be rolled out across all 12 participating clinical sites.
Lifestyle assessment
Another key milestone was developing and selecting questionnaires to explore lifestyle habits linked to metabolic dysfunction-associated steatotic liver disease (MASLD). The healthcare professionals at the 12 GRIPonMASH locations also received training in accurately capturing dietary information. The findings will provide valuable guidance for healthcare professionals, researchers, and patients in developing personalized lifestyle approaches.
Communication, dissemination and education
During the first year of the GRIPonMASH project, the groundwork was established for a solid communication, dissemination, and educational strategy. A key insight highlighted the critical importance of raising awareness about MASH among primary healthcare providers. To address this need, an awareness campaign was created, supported by concise educational modules that will be easily accessible on the project website.
About GRIPonMASH
GRIPonMASH is a consortium founded by the Julius Center and Julius Clinical (CRO, Zeist, NL) consisting of 27 involved parties dedicated to bring about a transformational change in the detection and diagnosis of MASH patients. The four year project is funded the Innovative Health Initiative Joint Undertaking (IHI) which is funded jointly by the European Union (represented by the European Commission) and the life science industries (represented by COCIR, EFPIA / Vaccines Europe, EuropaBio, MedTech Europe). The aim is to achieve better information, diagnosis and lifestyle advice on MASH. The aim is to increase the number of people diagnosed and aware of the lifestyle changes needed and decrease the number of people with MASH and liver cancer.
The project is coordinated by the Julius Center of UMC Utrecht in the Netherlands.
For questions, please contact: Project Management Office
in**@gr********.eu
